Go UK Bio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Go UK Bio


Pharmaceutical Technology Europe
Volume 24, Issue 1

Firstly, Happy New Year! Please help yourself to a slice of cake.


Rich Whitworth
Towards the end of last year, I attended the 8th bioProcessUK conference in Glasgow, Scotland, with the tagline "Advancing Next Generation Therapies." The meeting was held in the very fitting Glasgow Science Centre, a place where children young and old can be inspired by the science around them—the next generation of pharma industry employees perhaps? There was a clear agenda to the conference—how to ensure that advances made in research result in actual therapies.

In all areas of pharmaceutical development, one of the recurring challenges is scale-up, so of particular interest was a thought-provoking talk given by Roslin Cell's Aidan Courtney on scaling up cell manufacture from the point of view of translating research protocols into GMP processes. He noted, "the destination defines the journey," i.e., depending on the application of a particular cell therapy, the quantity of cells required for treatment becomes a crucial parameter. Courtney went on to provide numbers for a couple of example scale-up scenarios; ischemia therapy would probably require 108 cells per treatment, so estimating perhaps 10,000 treatments per year, the numbers start multiplying faster than the cells... He concluded that GMP translation and scale-up are challenges best addressed in tandem.

Bridging the gap between discovery into development and onto commercial scale manufacturing is something that our sister publication, BioPharm International, is addressing in collaboration with BIO SmartBrief: "Drug Development Basic Training". I encourage you to check out some of the weekly articles and podcasts at http://BioPharmInternational.com/biosmart/ and to sign up for BIO SmartBrief.

I leave you with the passionate words of this year's winner of the Peter Dunnill Award, Professor Mike Hoare from University College London, who concluded in his bioProcessUK presentation on ultra scale-down for enhanced bioprocess discovery: "Design for manufacture; design for lower cost."

Best wishes
Rich Whitworth

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here